13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01973491
(ClinicalTrials.gov)
February 28, 201423/10/2013ATX-MS-1467 in Multiple SclerosisAn Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple SclerosisMultiple SclerosisDrug: ATX-MS-1467Merck KGaANULLCompleted18 Years65 YearsAll37Phase 2Germany
2EUCTR2013-002916-28-LV
(EUCTR)
12/12/201316/10/2013An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple SclerosisAn Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis
MedDRA version: 20.0;Level: PT;Classification code 10067063;Term: Progressive relapsing multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: ATX-MS-1467
Product Code: MSC2358825A
INN or Proposed INN: MSC2304479A
INN or Proposed INN: MSC2304480A
INN or Proposed INN: MSC2304481A
INN or Proposed INN: MSC2304482A
Merck KGaANULLNot RecruitingFemale: yes
Male: yes
20Phase 2Russian Federation;Latvia